<DOC>
	<DOCNO>NCT00242918</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness combination docetaxel ZD1839 destroy prostate cancer removal prostate .</brief_summary>
	<brief_title>Safety Effectiveness Study Docetaxel ZD1839 Followed Removal Prostate Treat Prostate Cancer</brief_title>
	<detailed_description>It recognize subset patient high risk progression despite aggressive treatment localized disease time detection . The critical issue address micrometastatic disease already develop prior diagnosis . This study utilizes daily dos ZD1839 weekly docetaxel two cycle prior radical prostatectomy . ZD1839 demonstrate antiproliferative activity human tumor xenograft coadministration cytotoxic agent prostate cell line ( PC-3 TSU-PRI ) . The combination ZD1839 docetaxel report feasible acceptable toxicity profile . This phase II , single center trial specifically target patient high-risk adenosarcoma prostate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>prostate carcinoma : clinical stage T2b3 serum PSA &gt; 20 ng/ml Gleason sum score 810. clinical T2 patient eligible endorectal coil MRI show T3 disease , Gleason 4+3 cancer 5 biopsy ( minimum 10 biopsy total require ) ECOG performance status 0 , 1 2 adequate hematological , liver renal function exist peripheral neuropathy &lt; grade 1 ability tolerate oral medication . Concurrent prior treatment radiation , cytotoxic , biologic therapy prostate cancer major surgery within four week prior hormonal therapy ( except finasteride obstructive voiding symptom evidence metastatic disease , confirm physical examination , compute tomography abdomen pelvis within 45 day bone scan within 60 day sign informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>High risk</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>neoadjuvant</keyword>
</DOC>